SI3269716T1 - Nove spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj - Google Patents

Nove spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj

Info

Publication number
SI3269716T1
SI3269716T1 SI201431673T SI201431673T SI3269716T1 SI 3269716 T1 SI3269716 T1 SI 3269716T1 SI 201431673 T SI201431673 T SI 201431673T SI 201431673 T SI201431673 T SI 201431673T SI 3269716 T1 SI3269716 T1 SI 3269716T1
Authority
SI
Slovenia
Prior art keywords
treatment
pharmaceutical compositions
novel compounds
inflammatory disorders
disorders
Prior art date
Application number
SI201431673T
Other languages
English (en)
Slovenian (sl)
Inventor
Nicolas Desroy
Bertrand Heckmann
Reginald Christophe Xavier Brys
Agnes Marie Joncour
Christophe Peixoto
Xavier Marie Bock
Original Assignee
Galapagos N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos N.V. filed Critical Galapagos N.V.
Publication of SI3269716T1 publication Critical patent/SI3269716T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI201431673T 2013-03-14 2014-03-07 Nove spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj SI3269716T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781174P 2013-03-14 2013-03-14
EP17177371.6A EP3269716B1 (en) 2013-03-14 2014-03-07 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
SI3269716T1 true SI3269716T1 (sl) 2020-12-31

Family

ID=50236198

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201430403T SI2970255T1 (sl) 2013-03-14 2014-03-07 Spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj
SI201431673T SI3269716T1 (sl) 2013-03-14 2014-03-07 Nove spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201430403T SI2970255T1 (sl) 2013-03-14 2014-03-07 Spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj

Country Status (29)

Country Link
US (7) US8993590B2 (enExample)
EP (3) EP2970255B9 (enExample)
JP (2) JP6339595B2 (enExample)
KR (2) KR20210034098A (enExample)
CN (1) CN105143221B (enExample)
AR (1) AR095280A1 (enExample)
AU (3) AU2014231009B2 (enExample)
BR (1) BR112015020998B1 (enExample)
CA (1) CA2902103C (enExample)
CY (2) CY1119352T1 (enExample)
DK (2) DK3269716T3 (enExample)
ES (2) ES2824723T3 (enExample)
HR (2) HRP20171219T1 (enExample)
HU (2) HUE035966T2 (enExample)
IL (2) IL240531B (enExample)
LT (2) LT3269716T (enExample)
MX (1) MX358342B (enExample)
MY (1) MY170260A (enExample)
NZ (1) NZ711202A (enExample)
PH (1) PH12015502055A1 (enExample)
PL (2) PL2970255T3 (enExample)
PT (2) PT3269716T (enExample)
RU (1) RU2675818C2 (enExample)
SG (1) SG11201507224RA (enExample)
SI (2) SI2970255T1 (enExample)
TW (2) TWI695002B (enExample)
UY (1) UY35437A (enExample)
WO (1) WO2014139882A1 (enExample)
ZA (1) ZA201505909B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201914121YA (en) 2011-09-14 2020-03-30 Samumed Llc Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
ES2824723T3 (es) 2013-03-14 2021-05-13 Galapagos Nv Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
CN105339370B (zh) 2013-06-19 2017-09-15 加拉帕戈斯股份有限公司 用于治疗炎症性疾病的化合物和及其药物组合物
WO2015057823A1 (en) 2013-10-15 2015-04-23 Radux Devices, LLC Securing a medical device to a valve instrument
HUE057702T2 (hu) 2014-08-29 2022-05-28 Chdi Foundation Inc Szondák huntingtin fehérje képalkotáshoz
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
EP3370721A4 (en) 2015-11-06 2019-05-22 Samumed, LLC TREATMENT OF OSTEOARTHRITIS
WO2017192228A1 (en) * 2016-05-06 2017-11-09 Albert Einstein College Of Medicine, Inc. Pak1 inhibitors and uses thereof
EP3464285B1 (en) 2016-06-01 2022-09-21 BioSplice Therapeutics, Inc. Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
AU2017345699A1 (en) 2016-10-21 2019-05-16 Samumed, Llc Methods of using indazole-3-carboxamides and their use as Wnt/B-catenin signaling pathway inhibitors
DE112017005356T5 (de) 2016-10-24 2019-07-11 Precision Combustion, Inc. Festoxidzelle mit interner Heizeinrichtung
KR102558716B1 (ko) 2016-11-07 2023-07-21 사뮤메드, 엘엘씨 단일-투여량, 즉시-사용가능한 주사용 제제
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
GB201710851D0 (en) 2017-07-06 2017-08-23 Galápagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
KR20200040262A (ko) 2017-08-09 2020-04-17 갈라파고스 엔.브이. 섬유성 질병의 치료에 사용하기 위한 화합물 및 그의 약학 조성물
WO2019029620A1 (zh) * 2017-08-09 2019-02-14 广州市恒诺康医药科技有限公司 Atx抑制剂及其制备方法和应用
MX2020004810A (es) 2017-11-15 2020-08-13 Galapagos Nv Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
WO2019158107A1 (zh) * 2018-02-14 2019-08-22 苏州信诺维医药科技有限公司 一种杂环化合物、其应用及含其的药物组合物
US11679108B2 (en) 2018-05-24 2023-06-20 Guangzhou Henovcom Bioscience Co., Ltd. Aromatic heterocyclic compound, and pharmaceutical composition and use thereof
CA3089527A1 (en) * 2018-05-29 2019-12-05 Fronthera U.S. Pharmaceuticals Llc Autotaxin inhibitors and uses thereof
US10711000B2 (en) 2018-05-29 2020-07-14 Fronthera U.S. Pharmaceuticals Llc Autotaxin inhibitors and uses thereof
CA3103648A1 (en) 2018-07-27 2020-01-30 Mitsubishi Tanabe Pharma Corporation 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
GB201812861D0 (en) 2018-08-08 2018-09-19 Galapagos Nv Methods of administering therapy
BR112021005445A2 (pt) 2018-10-29 2021-06-15 Boehringer Ingelheim International Gmbh piridazinas
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TW202110831A (zh) * 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
US20220273752A1 (en) * 2019-07-03 2022-09-01 Cornell University Modulation of dendritic cell function by the phospholipid messenger lpa
US11485727B2 (en) * 2019-07-22 2022-11-01 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators
DK4003978T3 (da) 2019-07-22 2024-07-22 Boehringer Ingelheim Int N-methyl, n-(6-(methoxy)pyridazin-3-yl) aminderivater som autotaxin (atx) modulatorer til behandlingen af inflammatoriske luftvejs- eller fibrotiske sygdomme
US11465982B2 (en) * 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines
EP3782997A1 (en) 2019-08-19 2021-02-24 Galapagos N.V. Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases
WO2021043260A1 (zh) 2019-09-06 2021-03-11 湖北生物医药产业技术研究院有限公司 嘧啶类化合物及其制备方法
WO2021088957A1 (zh) * 2019-11-07 2021-05-14 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
CN111004235A (zh) * 2019-11-29 2020-04-14 沈阳药科大学 一种ATX抑制剂Ziritaxestat的合成方法
CN113493453B (zh) * 2020-04-07 2023-06-16 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
JP2023533294A (ja) * 2020-07-09 2023-08-02 スージョウ アーク バイオファーマシューティカル カンパニー リミテッド Ａｔｘ阻害剤及びその製造方法並びに使用
CN114315825A (zh) * 2020-09-30 2022-04-12 江西济民可信集团有限公司 吡啶并咪唑衍生物及其制备方法和应用
MX2023004115A (es) 2020-10-06 2023-05-03 Ildong Pharmaceutical Co Ltd Compuestos del inhibidor de la autotaxina.
US20240317736A1 (en) * 2020-11-04 2024-09-26 Xizang Haisco Pharmaceutical Co., Ltd. Deuterated derivative as atx inhibitor, and application thereof
CA3199039A1 (en) * 2020-11-16 2022-05-19 Qingan ZOU Imidazothiazole compounds, pharmaceutical compositions, and uses thereof
JP2024502337A (ja) 2021-01-05 2024-01-18 ザイダス ライフサイエンシズ リミティド オートタキシンの新規阻害剤
CN117098757A (zh) 2021-02-02 2023-11-21 里米诺生物科学有限公司 Gpr84拮抗剂和其用途
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
KR20240111790A (ko) * 2021-11-25 2024-07-17 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 삼중 융합 고리 유도체 및 이의 제조방법과 용도
WO2023235871A2 (en) * 2022-06-03 2023-12-07 Seer, Inc. Systems, compositions, and methods relating to neurodegenerative diseases
KR102587919B1 (ko) * 2022-07-22 2023-10-11 주식회사 넥스트젠바이오사이언스 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물
IL318576A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd Pyridoxine-substituted GPR84 antagonists and their uses
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
KR20250057800A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
GR1010570B (el) 2022-12-22 2023-11-17 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., 4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213611T3 (es) * 1999-10-08 2004-09-01 Grunenthal Gmbh Derivados biciclicos de imidazo-3-il-amina.
ATE432282T1 (de) * 2003-04-23 2009-06-15 Schering Corp 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
US20080015193A1 (en) 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
WO2008138842A1 (en) * 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
AU2009321867B2 (en) * 2008-12-01 2015-12-10 Merck Patent Gmbh 2,5-Diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer
CN102369195B (zh) 2009-04-02 2014-04-16 默克专利有限公司 自分泌运动因子抑制剂
TW201120043A (en) * 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
ES2646834T3 (es) * 2010-08-20 2017-12-18 Amira Pharmaceuticals, Inc. Inhibidores de autotaxina y usos de los mismos
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US9260416B2 (en) * 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
ES2824723T3 (es) * 2013-03-14 2021-05-13 Galapagos Nv Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios

Also Published As

Publication number Publication date
EP3269716B1 (en) 2020-09-16
HRP20171219T1 (hr) 2017-11-03
JP6517976B2 (ja) 2019-05-22
LT3269716T (lt) 2020-10-26
HUE035966T2 (en) 2018-05-28
HUE051195T2 (hu) 2021-03-01
CA2902103A1 (en) 2014-09-18
RU2015143430A (ru) 2017-04-18
PH12015502055B1 (en) 2016-01-18
EP2970255B9 (en) 2018-09-19
ES2638980T3 (es) 2017-10-24
US20200239466A1 (en) 2020-07-30
DK3269716T3 (da) 2020-10-19
EP3269716A1 (en) 2018-01-17
JP2018135350A (ja) 2018-08-30
JP6339595B2 (ja) 2018-06-06
IL256624A (en) 2018-02-28
MX2015011077A (es) 2015-10-29
SG11201507224RA (en) 2015-10-29
EP2970255B1 (en) 2017-08-02
PH12015502055A1 (en) 2016-01-18
CY1119352T1 (el) 2018-02-14
MY170260A (en) 2019-07-13
US9670204B2 (en) 2017-06-06
AU2019204539A1 (en) 2019-07-18
US10526329B2 (en) 2020-01-07
PL2970255T3 (pl) 2017-10-31
UY35437A (es) 2014-10-31
US20170362227A1 (en) 2017-12-21
TWI749290B (zh) 2021-12-11
TWI695002B (zh) 2020-06-01
AR095280A1 (es) 2015-09-30
CN105143221A (zh) 2015-12-09
PT3269716T (pt) 2020-10-09
AU2014231009A1 (en) 2015-09-10
US20160244443A1 (en) 2016-08-25
US10125132B2 (en) 2018-11-13
HRP20201641T1 (hr) 2020-12-25
US9249141B2 (en) 2016-02-02
US11072611B2 (en) 2021-07-27
AU2019204539B2 (en) 2021-01-21
KR102231637B1 (ko) 2021-03-25
RU2675818C2 (ru) 2018-12-25
DK2970255T3 (en) 2017-09-18
ES2824723T3 (es) 2021-05-13
CA2902103C (en) 2021-09-21
EP3760630A1 (en) 2021-01-06
WO2014139882A1 (en) 2014-09-18
EP2970255A1 (en) 2016-01-20
SI2970255T1 (sl) 2017-12-29
PT2970255T (pt) 2017-09-05
IL240531B (en) 2018-01-31
CN105143221B (zh) 2017-06-09
BR112015020998A2 (pt) 2017-07-18
ZA201505909B (en) 2021-09-29
US20190169184A1 (en) 2019-06-06
NZ711202A (en) 2019-04-26
AU2014231009B2 (en) 2017-10-05
CY1123521T1 (el) 2022-03-24
KR20150128995A (ko) 2015-11-18
TW201444835A (zh) 2014-12-01
IL240531A0 (en) 2015-10-29
AU2017286828A1 (en) 2018-01-18
BR112015020998B1 (pt) 2022-10-18
US20140303140A1 (en) 2014-10-09
IL256624B (en) 2019-09-26
US20150111872A1 (en) 2015-04-23
US8993590B2 (en) 2015-03-31
JP2016512208A (ja) 2016-04-25
LT2970255T (lt) 2017-12-11
KR20210034098A (ko) 2021-03-29
TW201936604A (zh) 2019-09-16
MX358342B (es) 2018-08-15
HK1249507A1 (en) 2018-11-02
PL3269716T3 (pl) 2021-02-08
US20230022534A1 (en) 2023-01-26
AU2017286828B2 (en) 2019-04-04
HK1219730A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
IL256624B (en) Pharmaceutical compounds and preparations thereof for the treatment of inflammatory disorders
IL257581A (en) New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
IL246833A0 (en) New salts and their pharmaceutical preparations for the treatment of inflammatory disorders
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
HUE059041T2 (hu) Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
GB201401086D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
LT3021873T (lt) Kompozicija, skirta uždegiminių sąnarių ligų gydymui
GB201315072D0 (en) Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders
GB201315079D0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
GB201314016D0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
GB201314015D0 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases